28bio is a neurotechnology company, formerly AxoSim, that engineers human brain tissue at scale to model memory, learning and cognition for neurological drug development. Its Nexon platform combines tissue engineering, neural interfacing and AI, and its CNS-3D brain organoids measure human neural activity to predict drug safety and efficacy before clinical trials; in its retrospective Endurance Study the organoids predicted clinical seizure liability with 83% sensitivity and 89% specificity, 13x more predictive than animal models. Based in Metairie in the New Orleans area, the company serves pharma customers running preclinical CNS safety and efficacy assessment.
1
Round
1
Industry
5
Tags
Oct 29, 2026
Latest raise
Funding activity · 1 round
Oct 29, 2026
$8.5M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
